The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light.

The pharma expects a modest financial headwind this year from changes to Medicare prescription drug benefits under the Inflation Reduction Act.

U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that ...

Pharmaceutical stocks can bring an element of safety to your portfolio. Why is this the case? These companies make drugs ...

Leading pharmaceutical and IT companies have said they will quit Ireland if a proposed ban on so-called forever chemicals is ...

Pfizer on Tuesday appealed a federal judge's refusal to award the drugmaker $75.2 million from a more than decade-old insider ...

Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on.

Pfizer divests $3.05 billion of Haleon shares, cutting its stake to 7.3% in a strategic shift to refocus on core ...

CEO Albert Bourla expressed modest optimism for Pfizer’s 2025 revenues at JPM 2025, supported by plans to prioritize R&D in oncology and obesity.

This month, pharma companies have announced plans to increase the prices of more than 250 branded drugs in the US.

The US could be the beneficiary of a potential blanket ban on the use of PFAS, better known as ‘forever chemicals’.

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.